Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 17, 2025

Data from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

CRCara A. RabikSWShu WangRCRitu Chadda

Discussion

Loading...

Member takes

Overview

Randomized trials show improved overall survival with blinatumomab in pediatric and adult BCP ALL, indicating its potential in chemotherapy consolidation.

Key Points

  • Blinatumomab significantly improves overall survival in B-cell precursor acute lymphoblastic leukemia patients undergoing chemotherapy.
  • In randomized trials, blinatumomab showed an overall survival hazard ratio of 0.42, indicating strong efficacy compared to chemotherapy alone.
  • Descriptive analyses from pediatric studies reinforced blinatumomab's effectiveness, particularly in high-risk acute lymphoblastic leukemia cases.
  • The safety profile of blinatumomab remains consistent across multiple studies, validating its use in various patient demographics.

Cite This Study

Rabik et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcadbhttps://doi.org/10.1158/1078-0432.c.8090655
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1FDA Approval Summary: Blinatumomab for the Treatment of B-cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy2025 · 8 citations
  2. 2Safety and efficacy of consolidation-Phase blinatumomab in newly diagnosed B-cell acute lymphoblastic leukemia : A systematic review and meta-analysis2025
  3. 3Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia2026 · 1 citations
  4. 4Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse2023 · 109 citations
  5. 5Bispecific monoclonal antibody blinatumomab in the first-line therapy of B-lineage acute lymphoblastic leukemia in children and adolescents: interim results of the Russian Ministry of Health approbation protocol2024